- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01136642
Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray
Background:
- Smoking is the leading cause of preventable death in the United States, and researchers are interested in gaining a better understanding of the perceived beneficial effects of nicotine to help improve treatment strategies for nicotine dependence. Understanding the conditions under which nicotine improves attention and cognitive processing may provide more useful information for this research.
- The ability to pay attention and filter relevant from irrelevant stimuli is central to all aspects of information-processing. Top-down and bottom-up attentional processes illustrate how the brain combines stimuli and goal-directed behaviors. Bottom-up processing is an unconscious response to sensory input; for instance, when the eyes automatically focus on a prominent image in a picture. Top-down processing is a conscious response to drive attention toward specific stimuli; for instance, when a person is asked to focus on a less immediately noticeable image in a picture. Researchers are interested in determining whether nicotine improves cognitive performance by acting on top-down or bottom-up attentional mechanisms.
Objectives:
- To investigate the effect of nicotine on the top-down and bottom-up mechanisms of attention in cigarette smokers.
Eligibility:
- Current smokers (at least 10 cigarettes per day for at least 1 year) between 18 and 55 years of age.
Design:
- This study will involve one training session and four experimental sessions.
- During the training session, participants will receive a sample dose of the nicotine nasal spray used in the study to determine if they can tolerate the effects.
- For each experimental session, participants will receive one dose of nicotine nasal spray (1 mg, 2 mg, or 3 mg) or placebo spray, followed by blood pressure and heart rate monitoring, performance of an attentional test, and questionnaires to rate participants perception of nicotine effectiveness. Participants may receive different doses at different sessions, and will not be told which dose they will receive at any given point.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective:
The objective is to investigate the dose-response effect of nicotine on the top-down and bottom-up mechanisms of attention in cigarette smokers.
Study population:
Male and nonpregnant-female smokers 18 to 55 years of age.
Design:
This study is a double-blind, placebo controlled trial of nicotine or placebo nasal sprays. Participants have five visits: a training session and four experimental sessions. Each participant receives a test dose of the nasal spray immediately following the training session to ascertain tolerability and become familiarized with the effect of the spray. One dose (0, 1.0, 2.0 or 3.0 mg) of nicotine nasal spray is administered at the beginning of each experimental session followed by the test battery.
Outcome Measures:
Outcome measures are vital signs, ratings of mood and drug effect, and performance (accuracy, response time) on a test of selective attention.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- National Institute on Drug Abuse, Biomedical Research Center (BRC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- 18-55 year old male and female cigarette smokers
smoke a minimum of 10 cigarettes per day for at least 1 year
--Drug Use Survey
estimated IQ score greater than or equal to 85
--Weschsler Abbreviated Scale of Intelligence (WASI; raw vocabulary cutoff 49)
urine cotinine concentration greater than or equal 100 ng/ml
- NicAlert reading greater than or equal to 3
EXCLUSION CRITERIA:
- definite plan to quit smoking in next 30 days
- consumption of more than 15 alcoholic drinks per week during the past month
use of any illicit drugs more than twice per week during the past month
--Drug Use Survey (items 2-4)
pregnant or nursing
--Urine pregnancy test
HIV positive
--Oral HIV test
- untreated cardiovascular or pulmonary disease
- use of nicotine replacement products, bupropion or varenicline, in the past 3 months if specifically used to stop smoking
Past history of schizophrenia or bipolar disorder.
Current Major Depression Disorder, Diagnosis or treatment for Major Depressive Disorder in past 12 months. (H&P)
Evidence of current ADHD by current diagnosis or medication or score on Adult Symptom Rating Scale; (> 16 on pt A or B must be evaluated by a counselor)
- SCL-90 > 65 (must be evaluated by a counselor)
- Beck Depression Inventory-II score greater than or equal to 14 (must be evaluated by a counselor)
vital signs (must be outside these parameters on more than two occasions separated by at least one day):
- systolic blood pressure: minimum 95, maximum 160 mm Hg
- diastolic blood pressure: minimum 40, maximum 95 mm Hg
- pulse: minimum 50, maximum 105 bpm
- respirations: minimum 8, maximum 24 breaths per minute
- nasal passages: no pathology that would preclude administration of nasal spray
- under the influence of a drug or alcohol at experimental sessions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Single Group Assignment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Performance (accuracy response time) on a test of selective attention.
|
Secondary Outcome Measures
Outcome Measure |
---|
Vital signs, ratings of mood and drug effect.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- 999910459
- 10-DA-N459
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nicotine Dependence
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruitingNicotine Dependence, CigarettesCzechia, Norway
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)WithdrawnCardiovascular Risk Factor | Nicotine Dependence | Nicotine Dependence, Cigarettes | Nicotine Withdrawal | Tobacco ToxicityUnited States
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruiting
-
Duke UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence, CigarettesUnited States
-
Milton S. Hershey Medical CenterTerminatedNicotine Dependence, CigarettesUnited States
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruitingNicotine Dependence Tobacco ProductNorway, Czechia
-
University of VermontNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence, CigarettesUnited States
-
Freedom Laser, Inc.NST Consultants, Inc.Completed
-
University of VermontNational Institute of General Medical Sciences (NIGMS)CompletedNicotine Dependence, CigarettesUnited States
Clinical Trials on Nicotrol
-
The Scripps Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedSmoking | AlcoholismUnited States
-
University of MinnesotaNational Institute on Drug Abuse (NIDA)Completed
-
Hartford HospitalUConn HealthCompletedTobacco Use DisorderUnited States
-
Vanderbilt University Medical CenterCompleted
-
Rutgers, The State University of New JerseyNational Institute on Drug Abuse (NIDA)CompletedSmoking Cessation | SchizophreniaUnited States
-
Vanderbilt University Medical CenterCompletedMajor Depressive DisorderUnited States
-
Vanderbilt University Medical CenterNational Institute of Mental Health (NIMH)RecruitingDepressive DisorderUnited States
-
UConn HealthEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedSmoking Cessation | Nicotine DependenceUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)Withdrawn
-
National Institute on Aging (NIA)Unknown